Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Avalide Articles

Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada

1 April 2012

Pharmacopeia intitiates Ph IIb trial of DARA drug

10 March 2008

FDA clears Avalide as initial high BP therapy

26 November 2007

Continued rebound of Plavix lifts Bristol-Myers Squibb's third quarter

5 November 2007

B-MS' 2nd-qtr income up 5.8% on Plavix resurgence; future cost cuts planned

6 August 2007

Bristol-Myers Squibb's 1st-qtr sales and profits down, as takeover talk continues

7 May 2007

B-MS swings to loss in 4th qtr due to Plavix

5 February 2007

Bristol-Myers Squibb's 3rd-qtr income down 65% to $388M, as sales fall 12.5%

6 November 2006

B-MS's earnings hit $714M in 1st-qtr

8 May 2006

One-time tax benefit drives Bristol-Myers Squibb 2nd-qtr profits up 90%

8 August 2005

DTB questions antihypertensives as first-line therapy for diabetes 2

13 June 2005

Bristol-Myers Squibb reports 16% fall in 3rd-qtr earnings, though sales rise 1%

8 November 2004

20% pharma sales rise boosts B-MS profits

9 February 2004

Sanofi-Synthelabo sales up 9% in 3rd quarter

1 November 1999

EC approves Sanofi's Coaprovel

22 October 1998

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS